Beyond The Abstract Prostate Cancer Volume At Biopsy Predicts Clinically Significant Upgrading

UroToday.com - Despite two decades of experience, the clinical evaluation of the prostate cancer patient in the context of PSA screening remains controversial. Many patients today have a low risk of disease-related mortality, and there is no clear consensus for their optimal treatment or whether they should be treated at all.

More: continued here

Filed under: Prostate on March 3rd, 2008